...
首页> 外文期刊>Medical dosimetry: official journal of the American Association of Medical Dosimetrists >Stereotactic radiotherapy for unilateral orbital lymphoma and orbital pseudo-tumors: a planning study.
【24h】

Stereotactic radiotherapy for unilateral orbital lymphoma and orbital pseudo-tumors: a planning study.

机译:立体定向放射治疗单侧眼眶淋巴瘤和眼眶假肿瘤:一项计划研究。

获取原文
获取原文并翻译 | 示例

摘要

Orbital lymphoma and Grave's ophthalmopathy (GO) are successfully treated with radiation therapy. The lenses are blocked to prevent cataract formation. However, blocking of the lens by traditional methods can be difficult for tumors located anteriorly and extending into the retrobulbar space. We present a series of 3 patients with orbital lymphoma and 1 with GO treated with stereotactic intensity modulated radiation therapy (IMRT) to spare normal structures, including the lens. Three patients with orbital lymphomas and 1 with unilateral GO were treated with IMRT using a linac with stereotactic capabilities. Avoidance structures included the ipsilateral lens and globe, the contralateral lens and globe, the chiasm, and the brainstem. Two patients with orbital lymphoma were treated with 24 Gy in 12 fractions, and 1 patient was treated with 30.6 Gy in 17 fractions. The patient with GO was treated with 20 Gy in 10 fractions. The dosimetry was analyzed to determine the dose to normal tissues. Patient follow-up varies between 8 and 24 months. The mean minimal dose to the ipsilateral lens was 13.6% of the total dose, the mean maximal dose was 33.5%, and the mean median dose was 19.3%. The mean median dose to the contralateral eye was 1.1% of the total dose. The mean median dose to the chiasm was 14.9% of the total dose. The mean median dose to the brainstem was 1.9% of the total dose. No cataracts or other complications were noted in the 4 patients treated with this technique so far. IMRT gives a more conformal treatment to the orbital contents while sparing normal tissues such as the ipsilateral lens and adjacent critical structures. This should result in fewer complications such as cataracts.
机译:放射疗法已成功治疗了眼眶淋巴瘤和格雷夫氏眼病。镜片被遮盖以防止白内障形成。然而,对于位于前方并延伸到球后间隙的肿瘤,用传统方法阻塞晶状体可能很困难。我们介绍了3例眼眶淋巴瘤患者和1例接受立体定向强度调制放射治疗(IMRT)治疗的GO,以保留包括晶状体在内的正常结构。使用具有立体定向能力的直线加速器,对IMRT治疗3例眼眶淋巴瘤和1例单侧GO的患者。回避结构包括同侧晶状体和球体,对侧晶状体和球体,the骨和脑干。 2例眼眶淋巴瘤患者接受24 Gy分12次治疗,1例患者接受30.6 Gy治疗17分。 GO患者接受了10次20 Gy的治疗。分析剂量测定法以确定对正常组织的剂量。患者随访时间为8到24个月。同侧晶状体的平均最小剂量为总剂量的13.6%,最大最大剂量为33.5%,平均中位剂量为19.3%。对侧眼的平均中位剂量为总剂量的1.1%。 as骨的平均中位剂量为总剂量的14.9%。脑干的平均中位剂量为总剂量的1.9%。迄今为止,在用该技术治疗的4名患者中未发现白内障或其他并发症。 IMRT对眼眶内容物进行更保形的治疗,同时保留正常组织,例如同侧晶状体和邻近的关键结构。这样可以减少并发症,例如白内障。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号